# US 5,352,700 A · Use of essential fatty acids for the preparation of a drug for the treatment of infantile seborrheic eczema

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 5,352,700 A
- Document ID: US5352700A
- Status: Granted
- Kind: A
- Application number: 07/777,306
- Filed: 1991-12-09
- Granted: 1994-10-04
- Earliest claimed: 1991-12-09
- Inventors: Anders Frithz; Anders Tollesson
- Web page: https://patentgrep.com/patent/US5352700A

## CPC

- A61K 31/20: having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61P 17/00: Drugs for dermatological disorders
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07C 57/03: Monocarboxylic acids
- C07C 57/12: Straight chain carboxylic acids containing eighteen carbon atoms
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07C: ACYCLIC OR CARBOCYCLIC COMPOUNDS

## Abstract

The use of essential fatty acids having 18-20 carbon atoms for producing a pharmaceutical preparation for the treatment of infantile seborrhoeic eczema or asteatotic eczema.

## Claims

### Claim 1

A method for the treatment of infantile seborrheic eczema comprising administering to a patient suffering from infantile seborrheic eczema a composition comprising at least one essential fatty acid having 18-20 carbon atoms in an amount sufficient for said treatment.

### Claim 2 (depends on 1)

A method according to claim 1 wherein said at least one essential fatty acid having a 18-20 carbon atoms is administered in composition form and wherein said composition comprises at least 0.1% of said at least one essential fatty acid.

### Claim 3 (depends on 1)

A method according to claim 1 wherein said at least one essential fatty acid is administered in composition form comprising 0.5-50% by weight of said at least one essential fatty acid having 18-20 carbon atoms, and at least one pharmaceutically acceptable carrier for said fatty acid.

### Claim 4 (depends on 1)

A method according to claim 1 wherein said at least one essential fatty acid is administered in composition form comprising 1-20% by weight of said at least one essential fatty acid having 18-20 carbon atoms, and at least one pharmaceutically acceptable carrier for said fatty acid.

### Claim 5 (depends on 1)

A method according to claim 1 wherein said at least one essential fatty acid is administered in composition form comprising 5-10% by weight of said at least one essential fatty acid having 18-20 carbon atoms, and at least one pharmaceutically acceptable carrier for said fatty acid.

### Claim 6 (depends on 1)

A method according to claim 1 wherein said at least one essential fatty acid is gammalinolenic acid.

### Claim 7 (depends on 1)

A method according to claim 1 wherein said composition consists essentially of a vegetable oil containing said at least one fatty acid having 18-20 carbon atoms.

### Claim 8 (depends on 1)

A method according to claim 1 wherein said composition consists essentially of evening primrose oil or borage oil.

### Claim 9 (depends on 1)

A method according to claim 1 wherein said treatment is by topical application and said composition is an ointment or cream.

### Claim 10 (depends on 1)

A method according to claim 1 wherein said composition further comprises 1-30% by weight of zinc based on the total composition, or 0.1-10% by weight of PGE.sub.1 or PGE.sub.2 based on the total composition, or a mixture thereof.

### Claim 11 (depends on 1)

A method according to claim 1 wherein said composition further comprises 15-25% by weight of zinc based on the total composition, or 0.1-2% by weight of PGE.sub.1 or PGE.sub.2 based on the total composition, or a mixture thereof.

### Claim 12 (depends on 1)

A method according to claim 1 wherein said administration is orally in an amount of 100-600 mg.

### Claim 13 (depends on 1)

A method in accordance with claim 1 wherein said administration is intravenous.